My account
Injectables Orals Peptides Human Growth Hormone SARMs
Sign in
A
Anastrozole
B
Bacteriostatic water Boldenone undecylenate
C
Clenbuterol Clomiphene citrate Cabergoline
D
Drostanolone enanthate Drostanolone propionate Dehydroepiandrosterone (DHEA)
E
Erythropoietin Exemestane
F
Fluoxymesterone
H
Human chorionic gonadotropin Human growth hormone (HGH)
L
Liothyronine sodium
M
Mecasermin Meldonium Mesterolone Methandienone Methenolone acetate Methenolone enanthate Melanotan-2
N
Nandrolone decanoate Nandrolone phenylpropionate
O
Oxandrolone Oxymetholone
S
Sildenafil citrate Stanozolol
T
Trenbolone enanthate Trestolone acetate Trenbolone acetate Testosterone undecanoate Testosterone propionate Testosterone base and suspension Tadalafil citrate Testosterone cypionate Testosterone enanthate Tamoxifen citrate Turinabol
Y
Yohimbine
Show 164 results
Manufacturers
Categories
Substances
Disagree
Home Driada Medical Driada Medical
Retatrutide
Retatrutide - Driada Medical

Retatrutide - Driada Medical

Brand:
Driada Medical
Category:
Peptides
Substance:
Retatrutide
Package:
10 mg
Price:
0
See options
Product Overview
Retatrutide is an investigational therapy targeting metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD. Originally developed to address obesity and metabolic dysfunction, it activates GIP, GLP-1, and glucagon receptors. It is not FDA-approved but showed significant liver fat reduction and weight loss in Phase 2 studies. No PCT is required. Its clinical exploration began in 2021, positioning Retatrutide as a potential breakthrough in MASLD and MASH management.
References:

Sanyal, A.J., Kaplan, L.M., Frias, J.P., Brouwers, B., Wu, Q., Thomas, M.K., Harris, C., Schloot, N.C., Du, Y., Mather, K.J., Haupt, A., and Hartman, M.L., 2024. Retatrutide effects on liver fat and metabolic outcomes in patients with MASLD. Nature Medicine.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Retatrutide by Driada Medical, consult with your doctor or healthcare professional.

Explore More Products
Reviews
Leave Review
FAQ
What condition is Retatrutide being developed to treat?
Retatrutide is being investigated as a treatment for metabolic dysfunction-associated steatotic liver disease (MASLD), a widespread chronic liver condition linked to obesity and insulin resistance.
References:

Sanyal, A.J., Kaplan, L.M., Frias, J.P., Brouwers, B., Wu, Q., Thomas, M.K., Harris, C., Schloot, N.C., Du, Y., Mather, K.J., Haupt, A., and Hartman, M.L., 2024. Retatrutide effects on liver fat and metabolic outcomes in patients with MASLD. Nature Medicine.

How does Retatrutide affect liver fat content?
In clinical studies, Retatrutide significantly reduced liver fat content in a dose-dependent manner over 24 weeks, showing promise in addressing MASLD more directly than existing treatments.
References:

Sanyal, A.J., Kaplan, L.M., Frias, J.P., Brouwers, B., Wu, Q., Thomas, M.K., Harris, C., Schloot, N.C., Du, Y., Mather, K.J., Haupt, A., and Hartman, M.L., 2024. Retatrutide effects on liver fat and metabolic outcomes in patients with MASLD. Nature Medicine.

What makes Retatrutide different from other incretin-based therapies?
Retatrutide targets three receptors—GIP, GLP-1, and glucagon—allowing it to engage multiple metabolic pathways simultaneously, which may enhance weight loss and liver health outcomes.
References:

Sanyal, A.J., Kaplan, L.M., Frias, J.P., Brouwers, B., Wu, Q., Thomas, M.K., Harris, C., Schloot, N.C., Du, Y., Mather, K.J., Haupt, A., and Hartman, M.L., 2024. Retatrutide effects on liver fat and metabolic outcomes in patients with MASLD. Nature Medicine.